These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28641379)

  • 1. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation.
    Hellfritzsch M; Grove EL; Husted SE; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Europace; 2017 Jul; 19(7):1091-1095. PubMed ID: 28641379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study.
    Pottegård A; Poulsen BK; Larsen MD; Hallas J
    J Thromb Haemost; 2014 Sep; 12(9):1413-8. PubMed ID: 25039280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.
    Degli Esposti L; Andretta M; Di Pasquale G; Gambera M; Saragoni S; Perrone V; Buda S
    Vasc Health Risk Manag; 2019; 15():429-437. PubMed ID: 31632047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
    De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
    J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
    Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ
    Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.
    Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A
    Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
    Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
    Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.